TEVA•benzinga•May 27, 2025 at 09:34 PM

Teva Pharmaceutical Industries Announces That FDA Granted Fast Track Designation For Investigational TEV-53408, An Anti-IL-15 Antibody, For The Treatment Of People With Celiac Disease On A Gluten-Free Diet; TEV-53408 Is Currently Being Evaluated In A Phas

No summary available.

Read the full article from the original source for complete details and context.

Article published on May 27, 2025 by benzinga